Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 5Active not recruiting 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Pancreatic Neoplasms 3Resectable Pancreatic Cancer 1Pancreatic Ductal Adenocarcinoma 1Adenocarcinoma of the Pancreas 1Adenocarcinoma 1

Interventions

pembrolizumab 1270Specimen Handling 921Magnetic Resonance Spectroscopy 832Carboplatin 829Cyclophosphamide 802Cisplatin 726Nivolumab 682Paclitaxel 639Radiotherapy 613Gemcitabine 578Biopsy 556Bevacizumab 477Dexamethasone 445fludarabine 405Docetaxel 382venetoclax 372Oxaliplatin 365Capecitabine 360Fluorouracil 358atezolizumab 345durvalumab 338Rituximab 336Drug Therapy 330Doxorubicin 319Radiosurgery 316Blood Specimen Collection 313Pemetrexed 308Standard of Care 306Ipilimumab 305Radiation 285

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
paricalcitol × 1 year × Clear all
NCT05365893 2026-05-22

PHL Treatment in Pancreatic Cancer

Fox Chase Cancer Center

Phase EARLY_PHASE1 Active not recruiting
20 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT03415854 2026-05-12

NABPLAGEMD

HonorHealth Research Institute

Phase 2 Completed
34 enrolled 11 charts
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT03138720 2026-04-22

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

HonorHealth Research Institute

Phase 2 Completed
40 enrolled 22 charts
Gastrointestinal

Resectable Pancreatic Cancer

NCT04524702 2026-01-23

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Emory University

Phase 2 Completed
10 enrolled 13 charts
Gastrointestinal

Pancreatic Neoplasms

NCT04054362 2025-11-21

PINBALL

Barts & The London NHS Trust

Phase 2 Completed
27 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02030860 2025-07-25

A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
15 enrolled
Gastrointestinal

Adenocarcinoma of the Pancreas

Data powered by HemOnc (CC BY 4.0) Colophon âš¡